Key Points
- Insider sale: Jacqueline Zummo sold 22,598 Protara (NASDAQ:TARA) shares on April 1 at an average price of $5.26, reducing her holding by 19.06% to 95,961 shares and generating roughly $118,865, according to the SEC filing.
- Market and analyst context: TARA trades near $5.11 with a market capitalization of about $276M, and analysts carry a consensus "Moderate Buy" rating with a consensus target price of $21.40 (individual targets range up to $27 while one analyst rates it a sell).
- Business and recent results: Protara is a clinical‑stage immunotherapy company focused on HPV-driven cancers with lead candidate PTX-35, and it recently reported an EPS miss of ($0.37) versus ($0.34) expected.
Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) insider Jacqueline Zummo sold 22,598 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total value of $118,865.48. Following the completion of the sale, the insider directly owned 95,961 shares in the company, valued at approximately $504,754.86. This represents a 19.06% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Protara Therapeutics Price Performance
Protara Therapeutics stock opened at $5.11 on Friday. The firm has a market capitalization of $276.35 million, a P/E ratio of -3.87 and a beta of 1.50. The stock has a fifty day moving average price of $6.05 and a two-hundred day moving average price of $5.56. Protara Therapeutics, Inc. has a 52-week low of $2.77 and a 52-week high of $7.82.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last issued its earnings results on Tuesday, March 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). On average, equities research analysts predict that Protara Therapeutics, Inc. will post -3.32 EPS for the current fiscal year.
Analysts Set New Price Targets
Several analysts have recently weighed in on the stock. JPMorgan Chase & Co. initiated coverage on shares of Protara Therapeutics in a report on Wednesday, March 4th. They set an "overweight" rating and a $27.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Protara Therapeutics in a research report on Thursday, January 22nd. Piper Sandler began coverage on Protara Therapeutics in a report on Wednesday, January 7th. They set an "overweight" rating and a $24.00 price target for the company. TD Cowen reiterated a "buy" rating on shares of Protara Therapeutics in a research report on Tuesday, March 10th. Finally, HC Wainwright reissued a "buy" rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $21.40.
Check Out Our Latest Stock Report on TARA
Hedge Funds Weigh In On Protara Therapeutics
Large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in shares of Protara Therapeutics during the fourth quarter valued at approximately $368,000. ADAR1 Capital Management LLC raised its position in Protara Therapeutics by 3,127.4% in the 4th quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company's stock worth $6,059,000 after purchasing an additional 1,101,576 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of Protara Therapeutics during the fourth quarter worth $615,000. Sphera Funds Management LTD. acquired a new position in shares of Protara Therapeutics during the fourth quarter valued at $3,464,000. Finally, Quadrature Capital Ltd lifted its stake in shares of Protara Therapeutics by 39.4% during the fourth quarter. Quadrature Capital Ltd now owns 24,184 shares of the company's stock valued at $129,000 after acquiring an additional 6,838 shares during the period. 38.13% of the stock is currently owned by institutional investors and hedge funds.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company's primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body's immune response to target tumor cells. Protara's therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.
Protara's lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
